Drug combination improves survival in muscle-invasive bladder cancer trial

· Science · United States

A large international clinical trial co-led by researchers at UCLA has found that a new treatment approach could help people with an aggressive form of bladder cancer live longer and reduce the chance the cancer returns or progresses. The benefit was described as particularly notable for patients who cannot receive standard chemotherapy. The findings cover muscle-invasive bladder cancer, a form in which the disease has grown into the muscle wall of the bladder.

Why it matters：Most bladder cancer patients who cannot take standard chemotherapy have limited options, so a combination that extends survival and delays progression in a large international trial could shift treatment guidelines.

Key points

  • The trial was large and international, co-led by UCLA researchers.
  • The approach reduced the chances of the cancer returning or progressing.
  • Patients unable to receive standard chemotherapy appeared to benefit most.

Sources (original reporting)

More stories from this day